the median survival time was 8.7 months,the clinical beneficial Rate(CBR)was 50.0%,and CA19-9 decreased by over 50% in 8 patients(47.1%).

• GEMOX组部分缓解(PR)2例；微效(MR)3例；稳定(D)6例；进展(PD)4例；治疗有效率达33.；3%25；中位生存期8